A 76 year old white woman died from massive pulmonary haemorrhage nine days after she was admitted to Parkland Memorial Hospital for evaluation of haemoptysis and rapidly progressive glomerulonephritis. The differential diagnosis of haemoptysis with rapidly progressive glomerulonephritis is presented with particular emphasis on Wegener's granulomatosis and microscopic polyarteritis. Necropsy showed a small vessel necrotising vasculitis associated with a focal segmental necrotising glomerulonephritis consistent with microscopic polyarteritis.
Case report A 76 year old white woman was admitted to the hospital for evaluation of fevers, patchy pulmonary infiltrates, and worsening renal function; she expired on the ninth hospital day.
She had been well until two months before admission to a hospital in Beaumont, Texas with fevers to 38-9°C, haemoptysis, oral ulcers, epistaxis, nasal congestion, and dyspnoea. The admission chest x ray showed a right upper lobe posterior segment cavitary infiltrate. Treatment was started with cefuroxime and she was treated parenterally for 10 days. Her sputum culture grew Klebsiella pneumoniae. The following evaluation was made: white blood cells 16 9-25 0x 109/1 with 12-15% eosinophils, packed cell volume 0-3, platelets 613 x 109/1, urine analysissp gr 1-005, pH 6-5, no In their prospective study of 85 patients there was a 1 6/1 male to female ratio, the mean age of Laboratory investigation shows that the erythrocyte sedimentation rate is characteristically very high. A normochromic/normocytic anaemia and leucocytosis are also common. Renal abnormalities include increased plasma creatinine, haematuria, and, less frequently, red cell casts. Rheumatoid factor was measured in 44 patients and was positive in 27. 12 14 16 Although granulomatosus necrotising vasculitis can be seen in biopsy specimens of the skin, sinus, or kidney, the lung has the greatest yield. 7 Nasopharyngeal involvement was common and included oral ulcers, sinusitis, and epistaxis. Abdominal involvement was also common, though this was not present in our patient. Finally, cardiovascular and neurological abnormalities were rare.
The laboratory investigations of all patients showed a raised erythrocyte sedimentation rate, anaemia, an abnormal creatinine concentration, and microscopic haematuria. Most had granular or red cell casts. Other significant laboratory results included a high prevalence ofleucocytosis with neutrophilia and thrombocytosis. Rheumatoid factor was positive in 41%.
If renal studies are excluded most of these laboratory abnormalities are non-specific and found to a greater or lesser extent in all types of vasculitis. An exciting, prospective controlled study recently published in the Lancet showed that autoantibodies against neutrophil cytoplasmic antigens were specific and sensitive for both Wegener's granulomatosis and microscopic polyarteritis.20 Controls were normal patients and those with pulmonary-renal syndromes. Nevertheless, more patients need to be studied before this test can be used as an important diagnostic aid in clinical medicine.
Renal biopsy specimens were obtained from 94% of patients. A focal segmental necrotising glomerulonephritis was found in all patients.9
Crescents were seen in 88%.
Yet, we are told that no evidence of a focal segmental necrotising glomerulonephritis was found in our patient. Because 100% of patients with microscopic polyarteritis in a previous study had this finding it might be thought that microscopic polyarteritis could be excluded as a diagnosis. The renal biopsy specimen was inadequate, however, as only six glomeruli were seen. Thus the characteristic lesion was not evident until necropsy.
Direct immunofluorescence staining was performed on biopsy specimens of 20 patients with microscopic polyarteritis and showed minimal deposition of C3 and even less deposition of IgG.9 This lack of significant immunofluorescence is consistent with all types of vasculitides, excluding Schonlein-Henoch purpura.
An open lung biopsy would probably be necessary to distinguish Wegener's granulomatosis from microscopic polyarteritis, however. Still, the distinction between these two entities was only of academic importance as the major consideration was treatment of rapidly progressive glomerulonephritis.
Although no controlled trials have been done, the standard treatment of systemic necrotising vasculitis with internal organ involvement is with a combination of cyclophosphamide and prednisone.8 The cyclophosphamide should be given in a dose of 1-5-2 mg/kg daily by mouth. If there is fulminant disease a dose of up to 4 mg/kg daily can be given for the first three days and then cut back to 2 mg daily. If the patient cannot tolerate drugs by mouth or there is intestinal involvement, the drug is given intravenously. The dose may be increased by 25 mg every two weeks until a clinical response occurs or toxicity develops. The drug should be continued for one year after a remission has occurred. The goal of therapy is to suppress disease activity while keeping the white blood cell count above 3-5x I09/1 to decrease the risk of infection.
Azathioprine is an alternative agent, but in the NIH experience it is less effective than cyclophosphamide.2' Still, it may be useful in patients who cannot tolerate the side effects of cyclophosphamide, such as leucopenia, haemorrhagic cystitis, or gonadal dysfunction. Both drugs take at least 10 days before any effect on disease activity is seen. Consequently, prednisone is added for immediate antiinflammatory and immunosuppressive effects. The recommended dose is 1-2 mg/kg daily in three to four divided doses. The divided dose early in treatment produces the maximum therapeutic response as the effect of prednisone is at a peak after four hours. After two weeks of continuous treatment the drug can be given as a single morning dose and withdrawn over three months.
Pulse therapy-that is, 1-2 g of methylprednisolone given intravenously over 30 minutes-is often used in severe cases of vasculitis. Although there are no data at present showing a benefit over high dose prednisone taken by mouth, it is reasonable to use this regimen in disease not responding to conventional steroid doses or in life threatening disease.
In addition to treating the kidney disease, high dose prednisone and pulse therapy have been successfully used to treat pulmonary haemorrhage.22 23 The combination of cyclophosphamide and prednisone has been very effective in treating Wegener's granulomatosis. Before this treatment the average one year survival was less than 20% with a mean of five months.24 With the aforementioned regimen 93% of patients experience a remission with a four year survival of 88%. 12 Less success has been obtained in microscopic polyarteritis. The five year actuarial survival was 65% in the Hammersmith study.9
At the NIH the increased mortality compared with that for patients with Wegener's granulomatosis might have been secondary to the 
